MX2007013327A - Formulaciones de liberacion prolongada. - Google Patents
Formulaciones de liberacion prolongada.Info
- Publication number
- MX2007013327A MX2007013327A MX2007013327A MX2007013327A MX2007013327A MX 2007013327 A MX2007013327 A MX 2007013327A MX 2007013327 A MX2007013327 A MX 2007013327A MX 2007013327 A MX2007013327 A MX 2007013327A MX 2007013327 A MX2007013327 A MX 2007013327A
- Authority
- MX
- Mexico
- Prior art keywords
- extended release
- release formulations
- formulation
- active ingredient
- wax
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Abstract
La presente invencion se refiere a una formulacion de liberacion prolongada que contiene un ingrediente activo pobremente soluble en agua, y a un metodo para preparar la formulacion. La formulacion contiene un material de liberacion prolongada basado en cera, que proporciona la liberacion prolongada del ingrediente activo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67444405P | 2005-04-25 | 2005-04-25 | |
PCT/US2006/015373 WO2006116247A1 (en) | 2005-04-25 | 2006-04-25 | Extended release formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007013327A true MX2007013327A (es) | 2008-04-21 |
Family
ID=36698750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007013327A MX2007013327A (es) | 2005-04-25 | 2006-04-25 | Formulaciones de liberacion prolongada. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060275367A1 (es) |
EP (1) | EP1877040A1 (es) |
JP (1) | JP2008539240A (es) |
AU (1) | AU2006239838A1 (es) |
BR (1) | BRPI0610257A2 (es) |
CA (1) | CA2605792A1 (es) |
MX (1) | MX2007013327A (es) |
RU (1) | RU2007143556A (es) |
WO (1) | WO2006116247A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007122636A1 (en) * | 2006-04-25 | 2007-11-01 | Panacea Biotec Ltd | Pharmaceutical compositions containing long chain fatty acids as excipients as well as a process for manufacturing the same |
AU2014201170B2 (en) * | 2006-12-20 | 2015-09-24 | Mylan Pharmaceuticals Ulc | Pharmaceutical composition comprising a hot-melt granulated lubricant |
JP5290198B2 (ja) * | 2006-12-20 | 2013-09-18 | ミラン ファーマシューティカルズ ユーエルシー | ホットメルト顆粒化潤滑剤を含んでなる医薬組成物 |
EP1972336A1 (en) * | 2007-03-19 | 2008-09-24 | LEK Pharmaceuticals D.D. | Hot-melt micropellets |
NZ602968A (en) | 2008-03-21 | 2014-04-30 | Mylan Pharmaceuticals Inc | Extended release formulation containing a wax |
BR112015000320B1 (pt) | 2012-07-12 | 2023-03-07 | SpecGx LLC | Composições farmacêuticas dissuasivas de abuso e seu processo de preparação |
CN104661653B (zh) * | 2012-09-27 | 2017-07-14 | 温德尔·G·门多萨 | 生产缓释柠檬酸钾蜡基质片剂的方法 |
US10369108B2 (en) * | 2013-03-15 | 2019-08-06 | Mylan Laboratories, Inc. | Hot melt granulation formulations of poorly water-soluble active agents |
WO2022266311A1 (en) * | 2021-06-16 | 2022-12-22 | Summit Biomedical Imaging | PARPi-FL FORMULATIONS |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2489439A (en) * | 1947-06-27 | 1949-11-29 | Samuel M Taylor | Record controlled printing machine |
US4443428A (en) * | 1982-06-21 | 1984-04-17 | Euroceltique, S.A. | Extended action controlled release compositions |
CH668187A5 (de) * | 1986-08-07 | 1988-12-15 | Ciba Geigy Ag | Therapeutisches system mit systemischer wirkung. |
USRE34990E (en) * | 1986-08-07 | 1995-07-04 | Ciba-Geigy Corporation | Oral therapeutic system having systemic action |
EP0361910B1 (en) * | 1988-09-30 | 1994-06-29 | Rhone-Poulenc Rorer Limited | Granular pharmaceutical formulations |
US5169645A (en) * | 1989-10-31 | 1992-12-08 | Duquesne University Of The Holy Ghost | Directly compressible granules having improved flow properties |
TW209174B (es) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
ES2180548T3 (es) * | 1992-10-16 | 2003-02-16 | Nippon Shinyaku Co Ltd | Metodo de obtencion de matrices de cera. |
KR100354702B1 (ko) * | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
DE4423078B4 (de) * | 1994-07-01 | 2005-01-13 | Awd.Pharma Gmbh & Co. Kg | Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung |
US5980942A (en) * | 1997-01-23 | 1999-11-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release matrix tablet formulations of carbamazepine |
US6296873B1 (en) * | 1997-01-23 | 2001-10-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release delivery system for carbamazephine derivatives |
DE19729487A1 (de) * | 1997-07-10 | 1999-01-14 | Dresden Arzneimittel | Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix |
DE19747261A1 (de) * | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
IL125244A (en) * | 1998-07-07 | 2002-12-01 | Yissum Res Dev Co | Pharmaceutical compositions containing low-melting waxes |
US6378526B1 (en) * | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
US6162466A (en) * | 1999-04-15 | 2000-12-19 | Taro Pharmaceutical Industries Ltd. | Sustained release formulation of carbamazepine |
US20020015730A1 (en) * | 2000-03-09 | 2002-02-07 | Torsten Hoffmann | Pharmaceutical formulations and method for making |
ITMI20012749A1 (it) * | 2001-12-21 | 2003-06-21 | Chiesi Farma Spa | Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut |
US6572889B1 (en) * | 2002-03-07 | 2003-06-03 | Noveon Ip Holdings Corp. | Controlled release solid dosage carbamazepine formulations |
US20040224017A1 (en) * | 2003-03-14 | 2004-11-11 | Nirmal Mulye | Process for preparing sustained release tablets |
US20040241234A1 (en) * | 2003-06-02 | 2004-12-02 | Alpharma, Inc. | Controlled release press-coated formulations of water-soluble active agents |
WO2005079752A2 (en) * | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
US20080075785A1 (en) * | 2006-09-22 | 2008-03-27 | San-Laung Chow | Controlled release hydrogel formulation |
-
2006
- 2006-04-25 BR BRPI0610257-3A patent/BRPI0610257A2/pt not_active IP Right Cessation
- 2006-04-25 MX MX2007013327A patent/MX2007013327A/es unknown
- 2006-04-25 CA CA002605792A patent/CA2605792A1/en not_active Abandoned
- 2006-04-25 US US11/410,502 patent/US20060275367A1/en not_active Abandoned
- 2006-04-25 EP EP06751176A patent/EP1877040A1/en not_active Withdrawn
- 2006-04-25 RU RU2007143556/15A patent/RU2007143556A/ru not_active Application Discontinuation
- 2006-04-25 WO PCT/US2006/015373 patent/WO2006116247A1/en active Application Filing
- 2006-04-25 AU AU2006239838A patent/AU2006239838A1/en not_active Abandoned
- 2006-04-25 JP JP2008508975A patent/JP2008539240A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1877040A1 (en) | 2008-01-16 |
US20060275367A1 (en) | 2006-12-07 |
AU2006239838A1 (en) | 2006-11-02 |
RU2007143556A (ru) | 2009-06-10 |
BRPI0610257A2 (pt) | 2010-06-08 |
JP2008539240A (ja) | 2008-11-13 |
WO2006116247A1 (en) | 2006-11-02 |
CA2605792A1 (en) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009117130A3 (en) | Extended release forumulation containing a wax | |
MX2007013327A (es) | Formulaciones de liberacion prolongada. | |
MX2008007307A (es) | Granulos/capsulas modificados que contienen ingrediente activo. | |
MX2007014892A (es) | Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico . | |
MX2007005156A (es) | Trehalosa y/o isomaltulosa como excipiente para formulaciones de aroma secas. | |
IL179568A0 (en) | Low-foaming aqueous formulations used for crop protection | |
WO2008063910A3 (en) | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions | |
PL1842534T3 (pl) | Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania | |
IL214617A (en) | Use of controlled release octreotide formulations for implant preparation | |
HK1141441A1 (en) | Sustained release pellets comprising wax-like material | |
WO2011087702A3 (en) | Aqueous antiperspirant/deodorant composition | |
IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
UA96449C2 (en) | Stable laquinimod preparations | |
IN2015DN03936A (es) | ||
WO2008128028A3 (en) | Solifenacin compositions | |
PL2079446T3 (pl) | Preparat paliperidonu o przedłużonym uwalnianiu | |
TW200800967A (en) | Benzimidazole thiophene compounds | |
JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
WO2010021607A3 (en) | Pharmaceutical formulation | |
IL191758A0 (en) | Composition with sustained release of the active ingredient, process for the preparation thereof and use thereof | |
WO2009105969A8 (zh) | 埃坡霉素类似物、其药物组合物、用途及其制备方法 | |
WO2009060952A1 (ja) | 新規製剤 | |
TW200638932A (en) | CCI-779 polymorph and use thereof | |
WO2009025792A3 (en) | Crystalline forms cinacalcet fumarate and cinacalcet succinate and processes for preparation thereof | |
MX2010008365A (es) | Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido. |